Drug Profile
DS 6016
Alternative Names: Anti ALK2 monoclonal antibody - Daiichi Sankyo/Saitama Medical University; Anti-ALK2 antibody - Daiichi Sankyo/Saitama Medical University; DS-6016; DS-6016aLatest Information Update: 18 Aug 2022
Price :
$50
*
At a glance
- Originator Daiichi Sankyo Company; Saitama Medical University
- Class Monoclonal antibodies
- Mechanism of Action ACVR1 protein inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- Phase I Fibrodysplasia ossificans progressiva
Most Recent Events
- 26 Jul 2022 Daiichi Sankyo completes a phase I trial in Fibrodysplasia ossificans progressiva (In volunteers) in Japan (SC, Injection) (NCT04818398)
- 01 Apr 2021 Phase-I clinical trials in Fibrodysplasia ossificans progressiva (In volunteers) in Japan (SC) (NCT04818398)
- 01 Apr 2021 DS 6016 is available for licensing as of 01 Apr 2021. https://www.daiichisankyo.com/partnering/